Andrx To Modify Fortamet Promotional Materials Due To Similarity With Sankyo's WelChol
This article was originally published in The Pink Sheet Daily
Executive Summary
The company has offered to make "certain changes" to the Fortamet promotional materials following notification from Sankyo of potential confusion with WelChol's trademark. Andrx says it does not know the "ultimate outcome of this matter."
You may also be interested in...
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles
Sepracor Lunesta Ads Are Top At Brand Recognition, IAG Research Finds
Sepracor's television ads for its sleep aid Lunesta create brand recognition better than other new prescription drug direct-to-consumer ads, according to an analysis performed by IAG Research